Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Pancreatic Cancer Metastatic × Irinotecan × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 213 Rectal Neoplasms 83 Colonic Neoplasms 82 Pancreatic Neoplasms 79 Stomach Neoplasms 64 Neoplasm Metastasis 41 Esophageal Neoplasms 39 Neoplasms 35 Small Cell Lung Carcinoma 28 Glioblastoma 27 Neuroblastoma 25 Lung Neoplasms 24 Brain Neoplasms 24 Glioma 23 Gliosarcoma 18 Carcinoma, Non-Small-Cell Lung 18 Adenocarcinoma Of Esophagus 18 Breast Neoplasms 17 Unspecified Adult Solid Tumor, Protocol Specific 16 Esophageal Squamous Cell Carcinoma 15 Central Nervous System Neoplasms 15 Astrocytoma 15 Adenocarcinoma 13 Oligodendroglioma 12 Gastrointestinal Neoplasms 10 Biliary Tract Neoplasms 10 Rhabdomyosarcoma 9 Gallbladder Neoplasms 9 Sarcoma, Ewing 8 Sarcoma 7

Interventions

Gemcitabine 2 toripalimab 1 surufatinib 1 sintilimab 1 folfirinox 1 chloroquine diphosphate 1 balstilimab 1 Taxes 1 Oxaliplatin 1 Irinotecan 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Cisplatin 1 Chloroquine 1 Celecoxib 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04469556 2026-02-20

PASS-01

University Health Network, Toronto

Phase 2 Completed

Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡